跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2008-005885-30-CZ
EUCTR2008-005885-30-CZ进行中（未招募）不适用

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED,SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSIO

Pfizer Ltd0 个研究点目标入组 150 人开始时间: 2008年12月10日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
发起方
Pfizer Ltd
入组人数
150
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Subjects must meet all of the following inclusion criteria prior to study entry to be eligible for enrollment into the study:
  • •1.Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  • •2.Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • •3.Has a current diagnosis of symptomatic PAH classified by one of the following:
  • •a.Idiopathic, or familial pulmonary arterial hypertension (IPAH or FPAH).
  • •b.PAH associated with one of the following connective tissue diseases:
  • •i.Systemic sclerosis (scleroderma).
  • •ii.Limited scleroderma.
  • •iii.Mixed connective tissue disease.
  • •iv.Systemic lupus erythematosus.
  • •v.Overlap syndrome.
  • •c.Exposure to legal drugs and toxins (eg, anorexigens, L-tryptophan, toxic rapeseed oil). Subjects with PAH caused by methamphetamine use are excluded.
  • •4.Has WHO functional class III symptoms.
  • •5.Is =16 and =80 years of age.
  • •6.Has 6MWT distances =150 and =450 meters and distance walked within 15% of one another on two consecutive tests on different days at Screening. Both tests must be =150 and =450 meters. If the test results are not congruent, both of the Screening 6MWT should be repeated 24 hours to 2 weeks after the first attempt and the results must be within 15% of one another. If after this attempt, the subject is still not eligible, the subject will be considered a screen failure and denied entry into the study.
  • •7.Had a ventilation-perfusion (V/Q) lung scan or spiral/helical/electron beam computed tomography (CT), or pulmonary angiogram within the 3 years prior to screening that shows no evidence of thromboembolic disease (i.e. should be normal or low probability for pulmonary embolism). If a V/Q scan is abnormal (i.e. is not normal or low probability), then a confirmatory CT, angiography or selective pulmonary angiography must exclude chronic thromboembolic disease.
  • •8.Had the diagnosis of PAH confirmed by a cardiac catheterization within 6 months prior to screening with the following values:
  • •a.Mean pulmonary artery pressure (mPAP) >25 mm Hg (at rest).
  • •b.Pulmonary capillary wedge pressure (PCWP) or left ventricular-end diastolic pressure =15 mm Hg; and
  • •c.Pulmonary vascular resistance (PVR) >3 mm Hg/L/min or 240 dynes*sec/cm5.
  • •9.If on calcium channel blockers, has been receiving a stable dose for at least 1 month prior to screening.
  • •10.If on vasodilators, digoxin, diuretics or spironolactone has been receiving a stable dose for at least 1 month prior to study screening.
  • •11.If on oxygen has been on a stable flow rate (two flow rates i.e. one at rest and one for exercise is permitted) for at least 1 month prior to study screening.
  • •12.If on corticosteroids, has been receiving a stable dose of =20 mg/day of prednisone (or equivalent dose, if other corticosteroid) for at least 1 month prior to study screening. If receiving treatment for CTD with any other drugs, doses should remain stable for the duration of the study.
  • •13.If on any medication belonging to the statin drug class eg, lovastatin, atorvastatin, has been receiving a stable dose for at least 3 months prior to study screening and maintained throughout the study.
  • •14.If on warfarin (Coumadin®) or other vitamin K antagonists, has been receiving a stable treatment for at least 1 month prior to study screening; titration to target international normalized

排除标准

  • •Subjects presenting with any of the following will not be included in the study:
  • •1.Participation in other studies (with an investigational drug or device that has not received regulatory approval) within 30 days before the current study begins (screening) and/or during study participation.
  • •2.Previous exposure to an endothelin receptor antagonist (ETRA) such as sitaxsentan, bosentan or ambrisentan.
  • •3.Is taking, or has an anticipated need for systemic administration (oral, intravenous (IV)) of cyclosporine A for the duration of the study.
  • •4.Chronic treatment with PAH-specific drugs prior to the first day of study Screening or during the study with any of the following listed below. As this study is intended for subjects naïve to specific PAH treatment chronic treatment is defined as treatment administered for 30 days or longer.
  • •a.Any prostacyclin or prostacyclin analogue.
  • •b.Any phosphodiesterase-5 (PDE-5) inhibitor. The use of PDE-5 inhibitors as needed for erectile dysfunction is permitted as long as the subject has not taken a dose within 48 hours of an efficacy assessment. In addition, the subject should not take more than 8 sildenafil tablets, 6 vardenafil tablets or 4 tadalafil tablets per month.
  • •c.Intravenous inotropes, or
  • •d.Inhaled nitric oxide (excluding acute vasodilator testing during diagnostic cardiac catheterization).
  • •5.Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Screening.
  • •6.Has pulmonary function tests within 3 months prior to screening that reveal evidence of significant parenchymal lung disease. Parenchymal lung disease may be measured post-bronchodilator use and is defined as:
  • •a.Total lung capacity <70% (predicted), must be measured for CTD subjects
  • •b.Forced expiratory volume in 1 second (FEV1 ) =70% (predicted), or
  • •c.Forced expiratory volume in 1 second/forced vital capacity ratio (FEV1/FVC) =60% (predicted).
  • •7.Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C).
  • •8.Has known human immunodeficiency virus (HIV) infection, under treatment with or has anticipated need for HIV specific antiretroviral therapy.
  • •9.Has hepatic dysfunction, defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >1.5 times the upper limit of the normal range or direct bilirubin >2 times the upper limit of the normal range at Screening or Baseline.
  • •10.Has chronic renal insufficiency as defined by serum creatinine >2.5 mg/dL at Screening or requires dialytic support.
  • •11.Has a hemoglobin concentration <10 g/dL at Screening.
  • •12.History of obstructive sleep apnea (treated or untreated).
  • •13.History of atrial septostomy.
  • •14.Has history of left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following:
  • •a.Repaired or unrepaired congenital heart disease (CHD).
  • •b.Aortic or mitral valve disease (stenosis or regurgitation) defined as more than minimum aortic insufficiency and more than moderate mitral regurgitation.
  • •c.Pericardial constriction.
  • •d.Restrictive or congestive cardiomyopathy.
  • •e.Left ventricular ejection fraction <40% by multiple gated acquisition scan (MUGA), angiography or echocardiography (ECHO).
  • •f.Left ventricular shortening fraction <22% by ECHO.
  • •g.Symptomatic corona

研究者

发起方
Pfizer Ltd

相似试验

进行中（未招募）
1 期
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED,SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSIOMedDRA version: 9.1Level: HLTClassification code 10037401Term: Pulmonary hypertensionsPulmonary arterial hypertension
EUCTR2008-005885-30-SKPfizer Limited150
进行中（未招募）
1 期
A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremiaMedDRA version: 18.0Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestations
EUCTR2014-000545-78-HURempex Pharmaceuticals, Inc.850
进行中（未招募）
1 期
A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremiaMedDRA version: 18.1Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestations
EUCTR2014-000545-78-SIRempex Pharmaceuticals, Inc.500
进行中（未招募）
1 期
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION WHO HAVE COMPLETED STUDY B1321001MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionPulmonary Arterial Hypertension
EUCTR2008-005887-14-SKPfizer Limited, Ramsgate Road, Sandwich, Kent, UK150
未知
不适用
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELIMUMAB (HGS 1006) ADMINISTERED SUBCUTANEOUSLY (SC) TO SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).
PER-046-12HUMAN GENOME SCIENCES, INC.,